Wojciech Larczyński

The Effect of N-Acetylcysteine on Proteinuria and Markers of Tubular Injury in Non-Diabetic Patients with Chronic Kidney Disease

B. Rutkowski, M. Renke, L. Tylicki, 2008, Kidney and Blood Pressure Research.

Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.

B. Rutkowski, M. Renke, L. Tylicki, 2010, Acta biochimica Polonica.

Nephroprotection in chronic kidney disease . A summary of research of the Gdansk Nehrology

S. Lizakowski, S. Małgorzewicz, M. Renke, 2014 .

[Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline].

B. Rutkowski, M. Renke, L. Tylicki, 2008, Przeglad lekarski.

Dual blockade of the renin–angiotensin–aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection: An open, controlled, randomized study

B. Rutkowski, M. Renke, L. Tylicki, 2008, Scandinavian journal of urology and nephrology.

Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.

B. Rutkowski, M. Renke, L. Tylicki, 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

High-dose angiotensin-converting enzyme inhibitor attenuates oxidative stress in patients with chronic kidney disease.

B. Rutkowski, M. Renke, L. Tylicki, 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Renal Protective Effects of the Renin-Angiotensin-Aldosterone System Blockade: From Evidence-Based Approach to Perspectives

B. Rutkowski, L. Tylicki, Wojciech Larczyński, 2005, Kidney and Blood Pressure Research.

[Pentoxifylline old drug or new hope for nephrology?].

B. Rutkowski, M. Renke, L. Tylicki, 2008, Przeglad lekarski.

Spironolactone attenuates oxidative stress in patients with chronic kidney disease.

B. Rutkowski, M. Renke, L. Tylicki, 2008, Hypertension.